Lin Shen, MD, PhD

Assistant Professor

Autoimmune rheumatic diseases, which constitute a broad range of chronic illnesses, cause significant morbidity and mortality in the US and worldwide. T cell receptor (TCR) recognition and signaling have long be recognized to play a critical role in the pathogenesis of autoimmune diseases. However, how altered TCR signaling strength affects immune tolerance and promotes autoimmunity remains incompletely understood. Dr. Shen’s research seeks to understand how abnormal TCR signaling resulting from mutations from human patients with complex autoimmune syndrome may alter T cell antigen sensitivity, affect T helper cell fate, and impair immune tolerance. Studying human monogenic diseases with known genetic defects and autoimmune phenotypes provides us with a unique opportunity for advancing our knowledge of disease pathogenesis of more common polygenic autoimmune diseases. These studies may also have implications in preventing cancer immunotherapy related adverse events and identification of new therapeutic targets for autoimmune diseases.
Education
Fellowship, 2017 - Rheumatology, University of California, San Francisco
Residency, 2014 - Internal Medicine, University of Pittsburgh Medical Center
PhD, 2010 - Pharmacology/Virology, Johns Hopkins University School of Medicine
MD, 2005 - , Peking Union Medical College
Publications
  1. Ashouri JF, Lo WL, Nguyen TTT, Shen L, Weiss A. ZAP70, too little, too much can lead to autoimmunity. 2021. PMID: 34923645


  2. Nguyen TTT, Wang ZE, Shen L, Schroeder A, Eckalbar W, Weiss A. Cbl-b deficiency prevents functional but not phenotypic T cell anergy. 2021. PMID: 33974042


  3. Au-Yeung BB, Shah NH, Shen L, Weiss A. ZAP-70 in Signaling, Biology, and Disease. 2017. PMID: 29237129


  4. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J, Shen L, Siliciano RF. A quantitative basis for antiretroviral therapy for HIV-1 infection. 2012. PMID: 22344296


  5. Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, Xing S, Siliciano RF. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. 2011. PMID: 21753122


  6. Sampah ME, Shen L, Jilek BL, Siliciano RF. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. 2011. PMID: 21502494


  7. McMahon MA, Parsons TL, Shen L, Siliciano JD, Siliciano RF. Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses. 2011. PMID: 21325417


  8. Bellows ML, Taylor MS, Cole PA, Shen L, Siliciano RF, Fung HK, Floudas CA. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework. 2010. PMID: 21081094


  9. Rabi SA, O'Connell KA, Nikolaeva D, Bailey JR, Jilek BL, Shen L, Page KR, Siliciano RF, Blankson JN. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. 2010. PMID: 21068257


  10. Shen L, Rabi SA, Siliciano RF. A novel method for determining the inhibitory potential of anti-HIV drugs. 2009. PMID: 19837466


  11. Yang HC, Shen L, Siliciano RF, Pomerantz JL. Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. 2009. PMID: 19336585


  12. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, Siliciano RF. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. 2008. PMID: 18552857


  13. Sedaghat AR, Dinoso JB, Shen L, Wilke CO, Siliciano RF. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. 2008. PMID: 18362342


  14. McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, Xing S, Bhat S, Hale B, Hegarty R, Chong CR, Liu JO, Siliciano RF, Thio CL. The HBV drug entecavir - effects on HIV-1 replication and resistance. 2007. PMID: 17582071